Richard M Bambury
Overview
Explore the profile of Richard M Bambury including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
861
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Joyce A, Murphy G, Heffron C, Aherne D, Bambury R
Cureus
. 2025 Feb;
17(2):e79524.
PMID: 40012695
Angiosarcoma is a rare, aggressive malignancy originating from endothelial cells and associated with a poor prognosis. Diagnosis is histologically challenging. We present a rare case of cardiac angiosarcoma involving multiple...
2.
Elhassan E, Girleanu C, Kelly P, Power D, Sweeney P, Mayer N, et al.
Cureus
. 2024 Aug;
16(7):e65621.
PMID: 39205743
A 57-year-old male underwent an open right radical nephrectomy in 2015 for a 3-cm kidney tumor which was classified at the time as a combined tubulocystic and collecting duct carcinoma....
3.
Weadick C, Goggin C, Keogh R, Murphy J, Feeley L, Bennett M, et al.
World J Oncol
. 2024 Jul;
15(4):640-647.
PMID: 38993253
Background: Soft tissue sarcoma (STS) is comprised of approximately 80 subtypes, with an incidence of 4 - 5 per 100,000 annually in Europe. The National Comprehensive Cancer Network (NCCN) guidelines...
4.
Cronin T, Ronayne C, ODonovan N, McGuinness E, Cooke K, Dennehy M, et al.
Ir J Med Sci
. 2024 May;
193(5):2171-2177.
PMID: 38806877
Background: Expanded access programs (EAPs) allow cancer patients with unmet clinical need to obtain access to pre-authorisation treatments. There is no standardised process for implementing these programs nationally, and real-world...
5.
Coakley K, Bambury R, McGuinness E, Dennehy M, Ronayne C, Cahill M, et al.
Ir J Med Sci
. 2024 Jan;
193(3):1191-1199.
PMID: 38194005
Background: While biologic drugs have demonstrated efficacy across a range of indications, patient access to these drugs is constrained due to their high cost. Biosimilars provide a means to increase...
6.
Keogh R, Harvey H, Brady C, Hassett E, Costelloe S, OSullivan M, et al.
J Cancer Policy
. 2024 Jan;
39:100466.
PMID: 38176467
Introduction: Cyberattacks represent a growing threat for healthcare delivery globally. We assess the impact and implications of a cyberattack on a cancer center in Ireland. Methods: On May 14th 2021...
7.
Carroll H, Broderick A, McCarthy O, Bambury R, Power D, Collins D, et al.
Omega (Westport)
. 2023 Sep;
:302228231196620.
PMID: 37670454
The COVID-19 pandemic compounded isolation for patients through social distancing measures and staff shortages. We were concerned about the impact of COVID-19 on the quality of care provided at end-of-life...
8.
Saab M, McCarthy M, Murphy M, Medved K, OMalley M, Bambury R, et al.
Support Care Cancer
. 2023 Aug;
31(9):530.
PMID: 37603072
Purpose: To identify supportive care interventions for men with urological cancers. Methods: Experimental studies conducted among men with any urological cancer were eligible for inclusion. Academic Search Complete, CINAHL Plus...
9.
Macanovic B, OReilly D, Harvey H, Hadi D, Cloherty M, ODea P, et al.
Digit Health
. 2023 Jul;
9:20552076231185428.
PMID: 37426594
Purpose: To investigate the feasibility of implementing a remote patient monitoring system using an electronic patient-reported outcomes (ePROs) platform in a tertiary cancer center in the Republic of Ireland. Methods:...
10.
Cronin C, Iqbal S, Farooq A, ODea P, Burke L, OReilly S, et al.
Lung Cancer Manag
. 2023 Jun;
12(1):LMT58.
PMID: 37283858
Aim: Adjuvant chemotherapy in NSCLC is associated with modest benefits and significant toxicity. We sought to evaluate the toxicity of adjuvant chemotherapy and disease-specific outcomes in a real-world population. Methods:...